UB Paderborn / Katalog / Suche / in CDI

Health-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study

Archives of orthopaedic and trauma surgery, 2012-11, Vol.132 (11), p.1583-1587

2012

Volltextzugriff (PDF)

Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study

Osteoarthritis and cartilage, 2013-01, Vol.21 (1), p.22-27

2013

Volltextzugriff (PDF)

Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk

Bone (New York, N.Y.), 2004-02, Vol.34 (2), p.344-351

2004

Volltextzugriff (PDF)

AB1372 Perception, knowledge and use by general practitioners of belgium of the frax® tool

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.716-716

2013

Volltextzugriff (PDF)

Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX®) to assess the 10-year probability of fracture

Rheumatology international, 2013-04, Vol.33 (4), p.979-983

2013

Volltextzugriff (PDF)

Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX® criteria

Rheumatology international, 2013-04, Vol.33 (4), p.973-978

2013

Volltextzugriff (PDF)

Development and assessment of the osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry

Gynecological endocrinology, 2002-06, Vol.16 (3), p.245-250

2002

Volltextzugriff (PDF)

Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis

Bone (New York, N.Y.), 2003-05, Vol.32 (5), p.541-545

2003

Volltextzugriff (PDF)

Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry

Gynecological endocrinology, 2002, Vol.16 (3), p.245-250

2002

Volltextzugriff (PDF)

Comprehensive therapy in osteoporosis using a single drug: from ADFR to strontium ranelate

Current medicinal chemistry, 2006-01, Vol.13 (13), p.1585

2006

Volltextzugriff (PDF)

The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial

Annals of internal medicine, 1998-07, Vol.129 (1), p.1

1998

Volltextzugriff (PDF)

Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in a sample of white women from Belgium

Bone (New York, N.Y.), 2001-10, Vol.29 (4), p.374-380

2001

Volltextzugriff (PDF)

A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis

Osteoporosis international, 1997-01, Vol.7 (5), p.488-495

1997

Volltextzugriff (PDF)

Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion

Calcified tissue international, 2002-02, Vol.70 (2), p.78-82

2002

Volltextzugriff (PDF)

Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy

Bone (New York, N.Y.), 2008-05, Vol.42 (5), p.832-836

2008

Volltextzugriff (PDF)

New serum biochemical markers (Coll 2-1 and Coll 2-1 NO 2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis

Osteoarthritis and cartilage, 2005-03, Vol.13 (3), p.258-265

2005

Volltextzugriff (PDF)

Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis

Bone (New York, N.Y.), 2001, Vol.28 (1), p.108-112

2001

Volltextzugriff (PDF)

Long‐term (3 years) prevention of trabecular postmenopausal bone loss with low‐dose intermittent nasal salmon calcitonin

Journal of bone and mineral research, 1994-01, Vol.9 (1), p.69-73

1994

Volltextzugriff (PDF)

Acute biochemical variations induced by four different calcium salts in healthy male volunteers

Osteoporosis international, 1993-09, Vol.3 (5), p.271-275

1993

Volltextzugriff (PDF)

Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX^sup Â^ criteria

Rheumatology international, 2013-04, Vol.33 (4), p.973

2013

Volltextzugriff (PDF)

Prediction of bone loss rate in healthy postmenopausal women

Calcified tissue international, 1997-03, Vol.60 (3), p.261-264

1997

Volltextzugriff (PDF)

Limited clinical utility of a self-evaluating risk assessment scale for postmenopausal osteoporosis: lack of predictive value of lifestyle-related factors

Calcified tissue international, 1999-11, Vol.65 (5), p.354-358

1999

Volltextzugriff (PDF)

Parathyroid hormone in the treatment of involutional osteoporosis: back to the future

Osteoporosis international, 1997-01, Vol.7 Suppl 3 (S3), p.S163-168

1997

Volltextzugriff (PDF)

Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation

Osteoporosis international, 1993-09, Vol.3 (5), p.261-264

1993

Volltextzugriff (PDF)

Bone mineral density of the spine and the hip measured with dual energy X-ray absorptiometry: normal range and fracture threshold for western European (Belgian) postmenopausal females

Clinical rheumatology, 1995-01, Vol.14 (1), p.68-75

1995

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Health-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study

Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study

Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk

AB1372 Perception, knowledge and use by general practitioners of belgium of the frax® tool

Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX®) to assess the 10-year probability of fracture

Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX® criteria

Development and assessment of the osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry

Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis

Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry

Comprehensive therapy in osteoporosis using a single drug: from ADFR to strontium ranelate

The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial

Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in a sample of white women from Belgium

A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis

Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion

Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy

New serum biochemical markers (Coll 2-1 and Coll 2-1 NO 2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis

Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis

Long‐term (3 years) prevention of trabecular postmenopausal bone loss with low‐dose intermittent nasal salmon calcitonin

Acute biochemical variations induced by four different calcium salts in healthy male volunteers

Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX^sup Â^ criteria

Prediction of bone loss rate in healthy postmenopausal women

Limited clinical utility of a self-evaluating risk assessment scale for postmenopausal osteoporosis: lack of predictive value of lifestyle-related factors

Parathyroid hormone in the treatment of involutional osteoporosis: back to the future

Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation

Bone mineral density of the spine and the hip measured with dual energy X-ray absorptiometry: normal range and fracture threshold for western European (Belgian) postmenopausal females

Suchergebnisse filtern